GlassScriptPhysician profile
Grace Y Ma
NPI 1992707335
$16,621.52
in general payments reported to CMS, 2019-2025
26 companies · $2,010 in 2025
The $2,010 reported for 2025 was more than what 83% of Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $445).
See the full distribution for Plastic and Reconstructive Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,432 · 2020: $2,002 · 2021: $2,705 · 2022: $1,460 · 2023: $3,539 · 2024: $3,475 · 2025: $2,010.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,358 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,200 · Travel and Lodging: $465.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,357.95 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,200.00 |
| Travel and Lodging | $465.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mentor Worldwide LLC | $5,518.08 | 2019-2025 | Mentor Memorygel Resterilizable Gel Sizer, Mentor Siltex Round Spectrum |
| Abbvie INC. | $2,603.23 | 2023-2025 | |
| Allergan, INC. | $2,147.68 | 2019-2022 | |
| Axogen | $1,650.61 | 2019-2025 | Avance Nerve Graft, Axoguard Ha+ Nerve Protector, Axoguard Nerve Cap |
| Rti Surgical, INC | $1,336.98 | 2023 | |
| Musculoskeletal Transplant Foundation INC. | $1,089.82 | 2019-2021 | |
| Bard Peripheral Vascular, INC. | $839.11 | 2021 | |
| Merz North America, INC. | $330.46 | 2019-2021 | |
| Integra Lifesciences Corporation | $209.05 | 2022-2025 | Integra, Integra Dermal Regeneration Template, Omnigraft |
| Davol INC. | $203.68 | 2022-2025 | Phasix Mesh, Arista |
| Smith+Nephew, INC. | $164.10 | 2022-2024 | Grafix, Stravix |
| Sientra, INC. | $101.87 | 2019 | |
| Stryker Corporation | $65.72 | 2024 | 1788 |
| Tela Bio, INC. | $55.53 | 2024-2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex), Ovitex 2s |
| Kci USA, INC. | $49.45 | 2019-2023 | Prevena Restor Bellaform, Prevena |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $38.23 | 2020-2024 | |
| Acelrx Pharmaceuticals, INC. | $33.80 | 2021 | |
| Ethicon US, LLC | $30.94 | 2025 | Megadyne |
| Kerecis Limited | $26.03 | 2019 | |
| Biocircuit Technologies INC | $23.23 | 2025 | Nerve Tape |
| Medtronic Vascular, INC. | $22.55 | 2019 | |
| Trevena, INC. | $20.19 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $18.38 | 2023 | Seglentis |
| Medtronic, INC. | $17.42 | 2021 | |
| Lemaitre Vascular, INC. | $14.95 | 2023 | Anastoclip Gc 8cm (Medium) |
| Apyx Medical Corporation | $10.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Ma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.